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Target Identification for a
Promising Anti-Lupus Drug
Target identification is one of the more difficult as- apects of modern chemical genetics. In this issue of fChemistry & Biology, Johnson et al. provide a com-
mpelling case for going through the trouble [1]. As a
byproduct of their identification of the cellular target
s
of an anti-lupus compound, they have uncovered a
apowerful tool for the characterization of a fascinating
i
molecular machine, the F1F0-ATP synthase.
r
sThe field of chemical biology/pharmacology is continu-
tously searching for new “drug-like” compounds and
mtheir respective protein targets. The fruits of these la-
fbors are transformed into pharmacological tools in the
tresearch setting and/or therapeutics in the clinical
crealm. Based on the order in which the screening is
tperformed, two major routes provide drugs: (1) the pro-
itein target is validated as a disease modifier prior to
fcompound screening or (2) the target is identified only
pafter a suitable drug is found. By the first method, a
ppotential target is validated, usually via genetic means
l(i.e., RNA interference, transgenic animals, epidemio-
ulogical studies, etc), and then diverse libraries of small
dmolecules are screened for inhibitory potential and/or
binding affinity. Although this approach is highly pro-
Oductive and expertly integrates elements of modern ge-
tnetics, it can’t claim to be the classical formula. The
msecond route to drug discovery emphasizes uncovering
tsmall molecules based on their function- or disease-
umodifying activity. The moniker “forward chemical ge-
tnetics” has been used in recent manifestations of this
uapproach [2–6], but because the identity of the target
uis (initially) of little consequence, it could also be called
sthe “shoot first, ask questions later” method. As a well-
fknown example, the analgesic effects of aspirin were
Oappreciated long before the physiological target was
tknown. Importantly, however, the eventual identification
bof the target can lead to exciting new discoveries in cell
obiology, signaling, and pathology.
Because the path to discovery is open-ended, the
b“shoot first” approach doesn’t require preexisting knowl-
Bedge of the proteins involved in a process. In fact, pre-
sviously under-appreciated functions of a protein target
lare often found. The high profile cancer target FRAP/
smTor provides one illustrative example. The path to
4identification of FRAP/mTor begins with the natural
Tproduct rapamycin, which was found to be a potent
mcell-cycle inhibitor in many cell types. The initial target
aof rapamycin in these cells was shown to be the cyto-
solic FK506 binding protein 12 (FKBP12) [7]. Binding of
drapamycin to FKBP12, however, doesn’t fully explain
sthe phenotypic outcomes of drug treatment. In two
tlandmark papers, the Schrieber and Snyder laborato-
Aries identified FRAP/mTor (and related yeast com-
hplexes) as the target that mediated rapamycin’s inter-
ruption of G1 progression [8, 9]. An explosion of (esearch aimed at treating cancer with FRAP/mTor in-
ibitors followed the identification of the drug’s target.
uring the past year, a manuscript containing the key-
ords “rapamycin” and “cancer” appeared in citation
atabases every other day, on average. In this case,
nd in others, the drug came first, target identification
ollowed, and important new understanding and excite-
ent came along for the ride.
As methods to generate large, diverse libraries of
mall molecules have become more sophisticated and
ccessible, researchers have pioneered simultaneous
mprovements in target identification methods. Recent
eviews (for examples, see references [10–14]) highlight
ome advances. In brief, one straightforward method
o identify the target of a drug is to immobilize the small
olecule on solid support and purify binding partners
rom cell lysates. Other methods include performing
hree-hybrid screens to find binding partners [15] and
omparing the phenotype of drug-treated cells with
hat of cells treated with control compounds or RNA
nterference libraries. Regardless of the method, identi-
ying the target of a drug can be complicated by the
resence of multiple potential binding partners in com-
lex cellular environments. Genetic methods (null al-
eles, conditional alleles, and/or RNA interference) are
sually required to provide definitive characterization of
rug specificity.
In this issue of Chemistry & Biology, the Glick and
pipari laboratories provide evidence that implicates
he F1F0-ATPase as the primary target of their immuno-
odulatory drug Bz-423 [1]. This manuscript marks
heir latest efforts to isolate compounds that can be
sed to study and, eventually, treat systemic lupus ery-
hematosus. In the context of this commentary, it is
seful to review what these labs have already contrib-
ted to the characterization of this drug’s activity; the
tory exemplifies what can be learned via the “shoot
irst” approach followed by careful target identification.
f particular interest are the insights into molecular mo-
or function and immunobiology that are revealed as a
yproduct of attempts to characterize the interaction
f Bz-423 with the F1F0-ATPase.
Bz-423 was uncovered as part of an effort to screen a
enzodiazepine library for modulators of autoimmunity.
z-423 fit the initial functional criteria and was found to
electively induce apoptosis in autoreactive B and T
ymphocytes by increasing intracellular reactive oxygen
pecies (ROS) [16]. Subsequently, administration of Bz-
23 was found to be effective in lupus mouse models.
he target of Bz-423 was unknown but thought to be a
itochondrial protein based on subcellular fraction-
tion results [16].
In this issue, Johnson et al report their use of phage
isplay (and other methods) to implicate the oligomycin
ensitivity conferring protein (OSCP) as the cellular
arget of Bz-423 [1]. OSCP is a subunit of the F1F0-
TPase and part of a regulatory hinge linking the ATP
ydrolysis/synthesis F1 region with the F0 proton pump
for reviews on the mechanism and structure of the
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415F1F0-ATPase see: [17, 18]). The stalk region does not
simply hold the two domains together but also trans-
fers mechanical force generated by proton transport
into chemical energy to drive ATP synthesis. Treatment
of cells with the OSCP ligand, oligomycin, causes a se-
vere drop in intracellular ATP levels and necrosis. Unlike
cells treated with oligomycin, Bz-423-treated cells have
stable ATP levels. The compound does, however, cause
apoptosis via a dramatic rise in ROS. Thus, Bz-423 may
be selectively toxic for activated lymphocytes because
of the greater numbers of mitochondria and higher ex-
pression of F1F0-ATPase/OSCP in these cells. As John-
son et al. discuss, one mechanistic scenario is that en-
dogenous control over reactive oxygen elimination is
disrupted in those cells that contain elevated target
levels and, thus, the potential for greater ROS prod-
uction. This result adds to a growing body of evidence
implicating energy homeostasis and mitochondrial
function as good targets for immune therapeutics and
specifically points to OSCP as a potential modifier.
The binding site of Bz-423 and the mechanism by
which it inhibits ATPase function remind us of another
strength of the “shoot first” approach. Little is known
about the structure or function of OSCP. Thus, pharma-
cological modulators of activity, such as Bz-423, may
yield important new insights into the regulation of ATP
synthesis. It is particularly interesting that two OSCP
binding compounds (oligomycin and Bz-423) induce
distinct responses. This demonstrates that individual
cycles of the ATPase motor can be trapped by small
molecules that bind OSCP. Thus, not only is Bz-423 a
potential therapeutic for lupus, but identification of its
target has also provided hints at the importance of en-
ergy homeostasis for autoimmunity and a pharmaco-
logical tool for interrogating a fascinating molecular
machine. Increased interplay between chemical-screen-ing centers and basic biological research should only
continue to provide such promising results.
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